Omnicell
OMCL (NASDAQ)
Omnicell, a small-cap healthcare technology firm, is recognized as one of Zacks' top small-cap stocks to consider for May 2026, trading under the ticker OMCL on NASDAQ. Despite a challenging five-year return of -68.40%, the company has recently rebounded with a strong one-year return of 48.62%. Analysts are optimistic, assigning a B+ rating with a median 12-month price target of $55.00, suggesting potential upside for investors looking for promising growth in the healthcare sector.
Pros:
- Strong upward momentum over the last 12 months
- Positive earnings report exceeding expectations
Cons:
- Negative returns over the past 5 years
- Flat performance year-to-date
Omnicell (OMCL) may appeal to investors seeking growth opportunities in the healthcare technology sector, particularly those willing to accept higher volatility given its significant five-year decline. With a recent rebound reflected in a 48.62% one-year return and a favorable analyst outlook, it could be suitable for those optimistic about the company’s future performance and potential recovery.